Instituto do Cancer de Sao Paulo - ICESP ( Site 0211)

São Paulo 01246-000

0 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Neoplasms

Studies at this site

• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) — Completed